T1	Participants 65 121	postmenopausal patients with metastatic breast carcinoma
T2	Participants 598 669	In 2 multiinstitutional prospective trials, 683 postmenopausal patients
T3	Participants 1703 1759	postmenopausal patients with metastatic breast carcinoma
